• Home
  • About
    • Group CEO
    • Management Team
    • Supervisory Board
    • Scientific Advisory Board
    • Affiliates
    • R&D Partnerships
    • Distributors
    • Quality Standards
    • Location
  • Services
    • Proteomics
    • Genomics Transcriptomics
    • Flow Cytometry
    • Assay Development
    • Monoclonal Antibodies
    • Biobanking
    • Biomarker Data Analyses
    • Biomarker Regulatory Services
  • Products
    • EASYCOV
    • FIMICS
    • BIOPRED
    • IVD Products
    • ELISA Kits
    • Recombinant Proteins
    • Monoclonal Abodies
    • Clinical Samples
    • Your Customized Kit
  • R&D
  • Quality
  • Investors
    • Financial Management
    • Financial Data
    • Shareholders
  • Media
    • Press Releases
    • Media News
    • Newsletters
    • Posts
    • All Media
  • Careers
Contact
Firalis
  • Home
  • About
  • Services
  • Products
  • R&D
  • Quality
  • Investors
  • Media

Press Releases

HAS valide le remboursement d'EasyCOV*

HAS valide le remboursement d'EasyCOV*

*La Haute Autorité de Santé (HAS) valide l’utilisation et recommande le remboursement du test salivaire EasyCOV® sous conditions.

28.11.2020

TACKLING COVID-19: THE "COVIRNA" PROJECT

TACKLING COVID-19: THE "COVIRNA" PROJECT

A diagnostic test funded by the EU, to improve surveillance and care of COVID-19 patients

27.11.2020

EasyCov: Covid-19 saliva test

EasyCov: Covid-19 saliva test

Firalis-produced and CE-marked "EasyCOV" saliva test, developed by Skillcell

18.06.2020

Theranostic Tool

13.03.2020

EU-funded (Eurostars) HeartLinc Program

13.03.2020

Launch of the Biopred panel

13.03.2020

Launch of the FiMICS® panel

13.03.2020

Fundraising by Amoneta Diagnostics

13.03.2020

USD 2 million by the Alzheimer’s Drug Discovery Foundation ...

13.03.2020

Champions de la croissance 2020

Firalis is placed as the 229th fastest growing French business in 2020, among 10k participants, as a result of a selection by the partnership of "Les Echos" and "Statista".

13.03.2020

Amoneta closes 2019 with fundraising of EUR 2.2 million

11.01.2020

Load More

Follow us on

Contact Firalis

Firalis Group

© Copyright 2020 all rights reserved. 

The company logos, products and service marks are trademarks or registered trademarks of Firalis.

-----------------------------------------------------------------------------------------------------------------------

Information addressed to health professionals. The products presented on this site are for professional use only and, where applicable, comply with the requirements of the IVD Directive 98/79 / EC. Instructions for use must be consulted before using these products.

-----------------------------------------------------------------------------------------------------------------------

Headquarter : 17 Rue du Fort 68330 Huningue FRANCE

follow Firalis on
Linkedin

EasyCOV

The first Covid-19 Rapid Salivary Test

99% Specific & 86% Sensitive

 

  • No more painful NP Swabs
  • No need for a Laboratory
  • Since 22/01/2021 officially equal to an RT-PCR Test!
  • Sample to Result time only 40 Minutes!
  • Result in an instant thanks to RT-LAMP Technology

 

LEARN MORE &

GET YOUR QUOTATION NOW !

EasyCOV

The first Covid-19 Rapid Salivary Test

99% Specific & 86% Sensitive

 

  • No more painful NP Swabs
  • No need for a Laboratory
  • Since 22/01/2021 officially equal to an RT-PCR Test!
  • Sample to Result time only 40 Minutes!
  • Result in an instant thanks to RT-LAMP Technology

 

LEARN MORE &

GET YOUR QUOTATION NOW !